Concurrent Investment Advisors LLC Boosts Stock Position in Hims & Hers Health, Inc. $HIMS

Posted by Francis Steltz on Sep 11th, 2026

Concurrent Investment Advisors LLC boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 109.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 35,272 shares of the company’s stock after purchasing an additional 18,459 shares during the period. Concurrent Investment Advisors LLC’s holdings in Hims & Hers Health were worth $1,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after buying an additional 319 shares in the last quarter. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Finally, Greenline Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $36,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 55,383 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47. Following the transaction, the chief financial officer owned 228,938 shares in the company, valued at approximately $8,033,434.42. This trade represents a 19.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. The trade was a 3.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 190,227 shares of company stock worth $6,133,613. 11.76% of the stock is owned by insiders.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

Negative Sentiment: The FTC reportedly accused Hims & Hers and certain executives of deceptive or unlawful business practices, including alleged misleading disclosures involving privacy, billing and prescription-related practices. The allegations have prompted claims that the company misled investors about its business and regulatory exposure. Hims & Hers Health Faces Securities Class Action After FTC Lawsuit
Negative Sentiment: Several investor-rights firms announced or promoted securities class actions covering shareholders who acquired HIMS securities between August 4, 2025, and July 29, 2026. The suits seek damages for alleged securities-law violations and could create litigation costs, management distraction and additional disclosure obligations. The allegations have not been proven in court. HIMS Investor Deadline and Class Action Announcement
Neutral Sentiment: Investors have until November 2, 2026, to seek appointment as lead plaintiff in the federal securities litigation. The deadline is a procedural step and does not itself establish liability or determine the eventual financial impact on Hims & Hers. Kaplan Fox Hims & Hers Lead Plaintiff Deadline

Analyst Ratings Changes

A number of analysts recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Needham & Company LLC increased their price target on Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Barclays decreased their price objective on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Friday, August 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Finally, TD Cowen lifted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $32.50.

Get Our Latest Analysis on HIMS

Hims & Hers Health Trading Down 1.4%

Shares of HIMS opened at $27.52 on Friday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The firm has a market capitalization of $6.42 billion, a P/E ratio of -43.69 and a beta of 2.42. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The stock’s fifty day simple moving average is $31.05 and its 200 day simple moving average is $27.16.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue was up 38.2% on a year-over-year basis. During the same period last year, the firm posted $0.17 EPS. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post -0.1 earnings per share for the current year.

Hims & Hers Health Company Profile

(Free Report)

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.